Form 4: Pacific Biosciences Director Receives Stock Option Grant

Director Christopher Gibson was granted 74,497 stock options in Pacific Biosciences of California, Inc. as part of standard compensation.

Summary

• Director Christopher Gibson received a grant of 74,497 stock options on June 3, 2026.
• The options have an exercise price of $1.58 per share.
• The options are set to expire on June 3, 2036.
• Vesting occurs monthly over a one-year period, contingent on continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices with no immediate impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of PACB common stock.
• Vesting is subject to the director's continued service to the company.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of monthly vesting over one year is consistent with standard director compensation packages for mid-cap biotech firms.
• The grant size is typical for board-level equity compensation in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options beginning July 3, 2026.

Key Dates

Keywords

PACB, Pacific Biosciences, Form 4, Insider Trading, Stock Options, Director Compensation